Invokana Clinical Trials

Prescribing Information
Key Studies
Click on a clinical study below:

Perkovic V, Jardine MJ, Neal B, et al.
The New England Journal of Medicine 2019;380(24):2295-2306

Perkovic V, de Zeeuw D, Mahaffey KW, et al.
The Lancet Diabetes & Endocrinology 2018;6(9):691-704

Zaccardi F, Webb DR, Htike ZZ, et al.
Diabetes, Obesity & Metabolism 2016;18(8):783-794

Afkarian M, Sacha M, Kestenbaum B, et al.
Journal of the American Society of Nephrology 2013;24(2):302-308
Invokana vs other SGLT2 inhibitors
Click on a clinical study below:

Zaccardi F, Webb DR, Htike ZZ, et al.
Diabetes, Obesity & Metabolism 2016;18(8):783-794

Evans M, Achha S, Neslusan C, et al.
Diabetes Therapy 2017;8(5):1175-1185

Schroeder M, et al.
Diabetalogia 2015;58(Suppl1):S1-S607 Abstract 727
Consistent reductions in HbA1c with Invokana 100 mg and 300 mg
Click on a clinical study below:

Lavalle-González FJ, Januszewicz A, Davidson J, et al.
Diabetologia 2013;56(12):2582-2592

Schernthaner G, Gross JL, Rosenstock J, et al.
Diabetes Care 2013;36(9):2508-2515

Stenlöf K, Cefalu WT, Kim KA, et al.
Diabetes, Obesity & Metabolism 2013;15(4):372-382

Forst T, Guthrie R, Goldenberg R, et al.
Diabetes, Obesity & Metabolism 2014;16(5):467-477

Wilding JP, Charpentier G, Hollander P, et al.
International Journal of Clinical Practice 2013;67(12):1267-1282

Cefalu WT, Leiter LA, Yoon KH, et al.
The Lancet 2013;382(9896):941-950
Invokana provides additional benefits of weight and blood pressure reduction
Click on a clinical study below:

Schernthaner G, Gross JL, Rosenstock J, et al.
Diabetes Care 2013;36(9):2508-2515

Stenlöf K, Cefalu WT, Kim KA, et al.
Diabetes, Obesity & Metabolism 2013;15(4)372-382

Forst T, Guthrie R, Goldenberg R, et al.
Diabetes, Obesity & Metabolism 2014;16(5):467-477

Cefalu WT, Leiter LA, Yoon KH, et al.
The Lancet 2013;382(9896):941-950

Neal B, Perkovic V, de Zeeuw D, et al.
Diabetes care 2015;38(3):403-411
Safety and tolerability
Click on a clinical study below:

Usiskin K, Kline I, Fung A, et al.
Postgraduate Medicine 2014;126(3):16-34

Nyirjesy P, Sobel JD, Fung A, et al.
Current Medical Research and Opinion 2014;30(6):1109-19

Yuan Z, DeFalco F, Ryan PB, et al.
Diabetes, Obesity & Metabolism 2018;20(3):582-589
Reporting adverse events
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.